nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia
|
Berger, Mathilde |
|
2019 |
112 |
C |
p. 94-97 |
artikel |
2 |
Adverse events 2.0—Let us get SERIOs
|
Heinzerling, Lucie |
|
2019 |
112 |
C |
p. 29-31 |
artikel |
3 |
Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials
|
Spunt, Sheri L. |
|
2019 |
112 |
C |
p. 98-106 |
artikel |
4 |
Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center
|
Harrison, Rebecca A. |
|
2019 |
112 |
C |
p. 83-93 |
artikel |
5 |
Comment on ‘Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery’
|
Ma, Bin |
|
2019 |
112 |
C |
p. 32-33 |
artikel |
6 |
Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system
|
Haydu, Lauren E. |
|
2019 |
112 |
C |
p. 9-11 |
artikel |
7 |
Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
|
Yuan, Peng |
|
2019 |
112 |
C |
p. 57-65 |
artikel |
8 |
HPV-circulating tumoural DNA by droplet-based digital polymerase chain reaction, a new molecular tool for early detection of HPV metastatic anal cancer? A case report
|
Veyer, David |
|
2019 |
112 |
C |
p. 34-37 |
artikel |
9 |
Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort
|
Tétu, Pauline |
|
2019 |
112 |
C |
p. 38-46 |
artikel |
10 |
Letter in response to ‘Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors’
|
Leclair, Valérie |
|
2019 |
112 |
C |
p. 47-48 |
artikel |
11 |
Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy
|
Wu, Szu-Yuan |
|
2019 |
112 |
C |
p. 109-117 |
artikel |
12 |
Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer
|
Argilés, Guillem |
|
2019 |
112 |
C |
p. 12-19 |
artikel |
13 |
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)
|
Pinto, Navin |
|
2019 |
112 |
C |
p. 66-79 |
artikel |
14 |
Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications
|
Van Rompay, Maria I. |
|
2019 |
112 |
C |
p. 118-126 |
artikel |
15 |
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer
|
Kim, Chan |
|
2019 |
112 |
C |
p. 20-28 |
artikel |
16 |
Statins – No more cream for cancer
|
Gillessen, S. |
|
2019 |
112 |
C |
p. 107-108 |
artikel |
17 |
The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma
|
Lutz, Manfred P. |
|
2019 |
112 |
C |
p. 1-8 |
artikel |
18 |
Timing of first-in-child trials of FDA-approved oncology drugs
|
Neel, Dylan V. |
|
2019 |
112 |
C |
p. 49-56 |
artikel |
19 |
Vision loss after chemotherapy: an irinotecan-induced retinopathy
|
Boilève, Alice |
|
2019 |
112 |
C |
p. 80-82 |
artikel |